Dataset Information

Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer.

ABSTRACT: BACKGROUND/AIM:Understanding prognostic factors of survival are important for treatment personalization in cancer patients. This study aimed to identify such factors for patients irradiated for bone metastases from prostate cancer. PATIENTS AND METHODS:Data from 74 patients irradiated between 01/2009 and 04/2019 were retrospectively evaluated. Ten characteristics were investigated for survival. RESULTS:Median survival in the entire cohort was 12 months. Survival rates at 3, 6, 9 and 12 months were 84%, 73%, 56% and 47%, respectively. On univariate analyses, the Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 was associated with improved survival (p<0.001), absence of visceral metastases (p=0.099) and only one irradiated metastatic site (p=0.099) showed a trend. On Cox regression analysis, only ECOG performance score (risk ratio=3.58, p<0.001) was significant. CONCLUSION:ECOG performance score is an independent prognostic factor of survival after irradiation of bone metastases from prostate cancer and may allow better personalization of care.

SUBMITTER: Haus R

PROVIDER: S-EPMC7157844 | biostudies-literature | 2020 Mar-Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer.

Haus Rapha R Janssen Stefan S Schild Steven E SE Rades Dirk D

In vivo (Athens, Greece) 20200301 2

<h4>Background/aim</h4>Understanding prognostic factors of survival are important for treatment personalization in cancer patients. This study aimed to identify such factors for patients irradiated for bone metastases from prostate cancer.<h4>Patients and methods</h4>Data from 74 patients irradiated between 01/2009 and 04/2019 were retrospectively evaluated. Ten characteristics were investigated for survival.<h4>Results</h4>Median survival in the entire cohort was 12 months. Survival rates at 3, ...[more]

PMID: 32111769

Similar Datasets

Project description:UnlabelledIxabepilone is an epothilone B analogue with activity in a variety of solid malignancies, including prostate cancer. The main dose-limiting toxicity of ixabepilone is myelosuppression when administered by using an every 3-week schedule. Here we evaluate the activity of a weekly ixabepilone in men with metastatic castrate-resistant prostate cancer to minimize hematologic toxicity.PurposeBMS-247550 (ixabepilone) is an epothilone B analogue with activity in taxane-resistant cancer cell lines. Here we report the activity and toxicity of ixabepilone, administered by using a weekly schedule, in men with metastatic castrate-resistant prostate cancer (CRPC).Experimental designPatients with metastatic CRPC received ixabepilone at 20 mg/m(2) intravenous weekly x 3, in 4-week cycles. This noncomparative study stratified patients to either a chemotherapy naive (CN), prior taxane (Tax) only, or 2 prior cytotoxic (TCx) chemotherapy arm. The primary endpoint was prostate-specific antigen response by using PCWG (Prostate Cancer Working Group) 1 criteria. Secondary endpoints included radiographic response when using RECIST (Response Evaluation Criteria In Solid Tumors).ResultsIn total, 124 patients were enrolled, of whom, 109 were eligible (35 CN, 42 Tax, and 32 TCx) for the primary response determination in this study. Prostate-specific antigen responses were seen in 12 (34.3%) of 35, 12 (28.6%) of 42, and 7 (21.9%) of 32 patients with the partial objective response in 5 (22.7%) of 22, 2 (8.0%) of 25, and 0 (0.0%) of 24 patients for the CN, Tax, and TCx arms, respectively. Significant (grade 3/4) neutropenia was seen in 6 (15.4%), 7 (14.6%), and 9 (25.0%); and grade 3/4 sensory neuropathy was seen in 8 (20.5%), 12 (25.0%), and 12 (33.3%) for CN, Tax, and TCx, respectively. Grade 3/4 thrombocytopenia was infrequent and seen in only one patient on the CN and the TCx arm.ConclusionIxabepilone was found to have an acceptable toxicity profile when administered by using a weekly schedule with less myelosuppression compared with prior studies when using the every 3-week schedule. Single-agent activity was observed and met prespecified activity levels for the Tax treated arm.

Project description:AimsThe ability of a patient to receive anti-cancer treatment depends on a variety of factors, including performance status (PS), which is typically measured using the Eastern Cooperative Oncology Group (ECOG) scale. This study hypothesized that there would be a strong and positive correlation between ECOG PS values and healthcare resource utilization (HCRU) and a strong and negative correlation with the use of anti-cancer therapy.Materials and methodsPatients with colorectal, lung or gastric cancer were included in this retrospective analysis of administrative claims data linked to electronic medical records (EMR). All-cause HCRU (hospitalization/inpatient care, emergency room visits, systemic anti-cancer therapy, radiation therapy, outpatient physician visits, hospice, home health care and key supportive care treatments such as anti-emetics, hematopoietic treatments, transfusions, and durable medical equipment) was evaluated by baseline ECOG PS value and PS over time. Adjusted multivariable regression analysis was used to assess the relationship between baseline ECOG PS and HCRU. Regression analyses were conducted to explore the relationship between other baseline variables and HCRU.ResultsThere were 1311 patients included in this study. There was low correlation between PS and any HCRU variable or receipt of anti-cancer therapy (correlation coefficients all <0.10). In regression analyses, the proportion of patients with poor PS (PS = 2+) who were hospitalized was not significantly different from those with good PS (PS = 0/1) (28.9% versus 19.3%, p = .07).LimitationsThe low rate of reporting of PS and the small sample size of patient groups in this study.ConclusionsThere is very little evidence of a relationship between ECOG PS and HCRU, ECOG PS, or anti-cancer therapy in this study, in part due to low rates of and lack of variability in reported PS. There is some evidence that baseline comorbidities were significantly associated with HCRU and should be accounted for in future research evaluating HCRU.

Dataset Information

Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer.

Publications

Eastern Cooperative Oncology Group Performance Score Is Associated With Survival After Radiotherapy of Bone Metastases from Prostate Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets